Press Releases
April 14, 2001
Debiopharm and Aurigene sign agreement for the development and commercialisation of Debio 1142, a novel inhibitor of an undisclosed oncology…
February 13, 2001
Dyax Corp. and Debiopharm S.A. report initiation of phase II clinical trial with EPI-HNE-4 for cystic fibrosis
January 10, 2001
Swiss drug developer Debiopharm S.A. achieves another success in the development of molecules for theraeutic use